Pax World Management LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 5.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,826 shares of the medical instruments supplier’s stock after selling 107 shares during the quarter. Pax World Management LLC’s holdings in Becton, Dickinson and were worth $356,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Janney Montgomery Scott LLC increased its holdings in shares of Becton, Dickinson and by 35.3% in the second quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after purchasing an additional 11,300 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Becton, Dickinson and by 1.4% in the second quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock worth $190,827,000 after purchasing an additional 13,263 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of Becton, Dickinson and by 5.8% in the second quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock worth $6,438,000 after purchasing an additional 1,819 shares during the last quarter. Union Bankshares Corp increased its holdings in shares of Becton, Dickinson and by 1.7% in the second quarter. Union Bankshares Corp now owns 22,335 shares of the medical instruments supplier’s stock worth $4,357,000 after purchasing an additional 381 shares during the last quarter. Finally, Boston Financial Mangement LLC increased its holdings in shares of Becton, Dickinson and by 10.2% in the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock worth $10,218,000 after purchasing an additional 5,152 shares during the last quarter. 87.12% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company (BDX) opened at 194.00 on Thursday. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63. The stock’s 50 day moving average price is $199.01 and its 200-day moving average price is $191.58. The company has a market cap of $44.15 billion, a PE ratio of 56.18 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.35 EPS. On average, analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.51%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/21/pax-world-management-llc-trims-stake-in-becton-dickinson-and-company-bdx.html.

In other news, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at approximately $5,279,917.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock valued at $15,242,688 in the last 90 days. Insiders own 1.40% of the company’s stock.

Several brokerages have weighed in on BDX. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company reissued a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $196.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.